Source Ledger · 54 Research Papers, Reviews, and Official Agency Records Verified Final URLs

Source archive for Melanotans

Every claim, receptor measurement, clinical outcome, laboratory assay, and regulatory quotation across this site traces to one of the 54 research papers, reviews, and official agency records cataloged below.

I. Discovery & Receptor Biology

16 sources
  1. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity

    Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, Hadley ME · Proceedings of the National Academy of Sciences of the United States of America (PNAS), 1980

    https://pubmed.ncbi.nlm.nih.gov/6777774/

  2. Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics

    Al-Obeidi F, Castrucci AM, Hadley ME, Hruby VJ · Journal of Medicinal Chemistry, 1989

    https://pubmed.ncbi.nlm.nih.gov/2555512/

  3. Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin

    Levine N, Sheftel SN, Eytan T, Dorr RT, Hadley ME, Weinrach JC, Ertl GA, Toth K, McGee DL, Hruby VJ · JAMA, 1991

    https://pubmed.ncbi.nlm.nih.gov/1658407/

  4. The cloning of a family of genes that encode the melanocortin receptors

    Mountjoy KG, Robbins LS, Mortrud MT, Cone RD · Science, 1992

    https://pubmed.ncbi.nlm.nih.gov/1325670/

  5. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans

    Valverde P, Healy E, Jackson I, Rees JL, Thody AJ · Nature Genetics, 1995

    https://pubmed.ncbi.nlm.nih.gov/7581459/

  6. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study

    Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME · Life Sciences, 1996

    https://pubmed.ncbi.nlm.nih.gov/8637402/

  7. Targeted disruption of the melanocortin-4 receptor results in obesity in mice

    Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P, Lee F · Cell, 1997

    https://pubmed.ncbi.nlm.nih.gov/9019399/

  8. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans

    Krude H, Biebermann H, Luck W, Horn R, Brabant G, Grüters A · Nature Genetics, 1998

    https://pubmed.ncbi.nlm.nih.gov/9620771/

  9. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study

    Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N · The Journal of Urology, 1998

    https://pubmed.ncbi.nlm.nih.gov/9679884/

  10. PT-141: a melanocortin agonist for the treatment of sexual dysfunction

    Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY · Annals of the New York Academy of Sciences, 2003

    https://pubmed.ncbi.nlm.nih.gov/12851303/

  11. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization

    Hadley ME, Dorr RT · Peptides, 2006

    https://pubmed.ncbi.nlm.nih.gov/16412534/

  12. Central role of p53 in the suntan response and pathologic hyperpigmentation

    Cui R, Widlund HR, Feige E, Lin JY, Wilensky DL, Igras VE, D'Orazio J, Fung CY, Schanbacher CF, Granter SR, Fisher DE · Cell, 2007

    https://pubmed.ncbi.nlm.nih.gov/17350573/

  13. Melanocortin Receptors, Melanotropic Peptides and Penile Erection

    King SH, Mayorov AV, Balse-Srinivasan P, Hruby VJ, Vanderah TW, Wessells H · Current Topics in Medicinal Chemistry (via PMC), 2007

    https://pmc.ncbi.nlm.nih.gov/articles/PMC2694735/

  14. Structure, function and regulation of the melanocortin receptors

    Yang Y · European Journal of Pharmacology (via PMC), 2011

    https://pmc.ncbi.nlm.nih.gov/articles/PMC3095696/

  15. The Melanocortin Receptor System: A Target for Multiple Degenerative Diseases

    Cai M, Hruby VJ · Current Protein & Peptide Science, 2016

    https://pubmed.ncbi.nlm.nih.gov/26916163/

  16. Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin

    Yuan XC, Tao YX · Biomolecules (via PMC), 2022

    https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/

II. Prescription Medicines & Pivotal Clinical Trials

14 sources
  1. Afamelanotide for Erythropoietic Protoporphyria

    Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, Bloomer J, Edwards C, Neumann NJ, Parker C, Phillips JD, Lim HW, Hamzavi I, Deybach JC, Kauppinen R, Rhodes LE, Frank J, Murphy GM, Karstens FPJ, Sijbrands EJG, de Rooij FWM, Lebwohl M, Naik H, Goding CR, Wilson JHP, Desnick RJ · The New England Journal of Medicine (via PMC), 2015

    https://pmc.ncbi.nlm.nih.gov/articles/PMC4780255/

  2. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

    Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA · Obstetrics & Gynecology, 2019

    https://pubmed.ncbi.nlm.nih.gov/31599840/

  3. SCENESSE (afamelanotide) implant, for subcutaneous use — Prescribing Information

    U.S. Food and Drug Administration (FDA) · U.S. Food and Drug Administration, 2019

    https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf

  4. Orphan Drug Designations and Approvals: Afamelanotide (SCENESSE)

    U.S. Food and Drug Administration (FDA), Office of Orphan Products Development · U.S. Food and Drug Administration, 2019

    https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=263208

  5. VYLEESI (bremelanotide injection), for subcutaneous use — Prescribing Information

    U.S. Food and Drug Administration (FDA) · U.S. Food and Drug Administration, 2019

    https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf

  6. NDA 210557 Approval Letter: Vyleesi (bremelanotide) subcutaneous injection

    U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research · U.S. Food and Drug Administration, 2019

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/210557Orig1s000ltr.pdf

  7. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

    Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, De Waele K, Farooqi IS, Gonneau-Lejeune J, Gordon G, Kohlsdorf K, Poitou C, Puder L, Swain J, Stewart M, Yuan G, Wabitsch M, Kühnen P; Setmelanotide POMC and LEPR Phase 3 Trial Investigators · The Lancet Diabetes & Endocrinology, 2020

    https://pubmed.ncbi.nlm.nih.gov/33137293/

  8. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period

    Haqq AM, Chung WK, Dollfus H, Haws RM, Martos-Moreno GÁ, Poitou C, Yanovski JA, Mittleman RS, Yuan G, Forsythe E, Clément K, Argente J · The Lancet Diabetes & Endocrinology, 2022

    https://pubmed.ncbi.nlm.nih.gov/36356613/

  9. IMCIVREE (setmelanotide) injection, for subcutaneous use — Prescribing Information (Revised 12/2024)

    U.S. Food and Drug Administration (FDA) · U.S. Food and Drug Administration, 2024

    https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213793s007lbl.pdf

  10. An overview of benefits and risks of chronic melanocortin-1 receptor activation

    Böhm M, Robert C, Malhotra S, Clément K, Farooqi S · Journal of the European Academy of Dermatology and Venereology (via PMC), 2025

    https://pmc.ncbi.nlm.nih.gov/articles/PMC11664455/

  11. IMCIVREE (setmelanotide) injection, for subcutaneous use — Prescribing Information (Revised 03/2026)

    U.S. Food and Drug Administration (FDA) · U.S. Food and Drug Administration, 2026

    https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf

  12. Setmelanotide for the Treatment of Acquired Hypothalamic Obesity

    Miller JL, van Santen HM, Phillips SA, Hamilton J, Aberle J, Sathyapalan T, Mohamed Z, McCormack SE, Shoemaker AH, Kelsey MM, Ghalib L, Stalla G, Thaker VV, Habiby R, Ode KL, Wabitsch M, Dattani M, Abuzzahab MJ, Abdullatif H, Morgan R, Stefater-Richards M, Aroda VR, Friedrich C, Han JC, Ono H, Nagasaki K, Tanaka T, Isojima T, Arima H, Scimia C, Yuan G, Müller HL, Roth CL; TRANSCEND Trial Group · The New England Journal of Medicine, 2026

    https://pubmed.ncbi.nlm.nih.gov/42418774/

  13. Scenesse (afamelanotide) — European Public Assessment Report (EPAR)

    European Medicines Agency (EMA) · European Medicines Agency (Product information last updated 07/10/2026), 2026

    https://www.ema.europa.eu/en/medicines/human/EPAR/scenesse

  14. Imcivree (setmelanotide) — European Public Assessment Report (EPAR)

    European Medicines Agency (EMA) · European Medicines Agency (Last updated 27/05/2026), 2026

    https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree

III. Online Lab Assays & Clinical Case Reports

17 sources
  1. Melanotropic peptides: more than just 'Barbie drugs' and 'sun-tan jabs'?

    Langan EA, Nie Z, Rhodes LE · British Journal of Dermatology, 2010

    https://pubmed.ncbi.nlm.nih.gov/20545686/

  2. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis

    Nelson ME, Bryant SM, Aks SE · Clinical Toxicology, 2012

    https://pubmed.ncbi.nlm.nih.gov/23121206/

  3. Melanotan and the posterior reversible encephalopathy syndrome

    Kaski D, Stafford N, Mehta A, Jenkins IH, Malhotra P · Annals of Internal Medicine, 2013

    https://pubmed.ncbi.nlm.nih.gov/23648958/

  4. Melanoma associated with the use of melanotan-II

    Hjuler KF, Lorentzen HF · Dermatology, 2014

    https://pubmed.ncbi.nlm.nih.gov/24355990/

  5. Microbiological contamination in counterfeit and unapproved drugs

    Pullirsch D, Bellemare J, Hackl A, Trottier YL, Mayrhofer A, Schindl H, Taillon C, Gartner C, Hottowy B, Beck G, Gagnon J · BMC Pharmacology and Toxicology (via PMC), 2014

    https://pmc.ncbi.nlm.nih.gov/articles/PMC4088308/

  6. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet

    Breindahl T, Evans-Brown M, Hindersson P, McVeigh J, Bellis M, Stensballe A, Kimergård A · Drug Testing and Analysis, 2015

    https://pubmed.ncbi.nlm.nih.gov/24771717/

  7. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review

    Habbema L, Halk AB, Neumann M, Bergman W · International Journal of Dermatology, 2017

    https://pubmed.ncbi.nlm.nih.gov/28266027/

  8. Are injectable illegal polypeptide drugs safe? Case report demonstrating the presence of haemolytic Bacillus cereus in 2 illegal peptide drugs

    Janvier S, Wattijn E, Botteldoorn N, De Spiegeleer B, Deconinck E, Vanhee C · Drug Testing and Analysis, 2018

    https://pubmed.ncbi.nlm.nih.gov/28941153/

  9. Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market

    Janvier S, Cheyns K, Canfyn M, Goscinny S, De Spiegeleer B, Vanhee C, Deconinck E · Talanta, 2018

    https://pubmed.ncbi.nlm.nih.gov/30029448/

  10. Falsification of biotechnology drugs: current dangers and/or future disasters?

    Janvier S, De Spiegeleer B, Vanhee C, Deconinck E · Journal of Pharmaceutical and Biomedical Analysis, 2018

    https://pubmed.ncbi.nlm.nih.gov/30165334/

  11. Melanotan-induced priapism: a hard-earned tan

    Dreyer BA, Amer T, Fraser M · BMJ Case Reports, 2019

    https://pubmed.ncbi.nlm.nih.gov/30796078/

  12. Melanotan II: a possible cause of renal infarction: review of the literature and case report

    Peters B, Hadimeri H, Wahlberg R, Afghahi H · CEN Case Reports, 2020

    https://pubmed.ncbi.nlm.nih.gov/31953620/

  13. Melanotan Tanning Injection: A Rare Cause of Priapism

    Mallory CW, Lopategui DM, Cordon BH · Sexual Medicine (via PMC), 2021

    https://pmc.ncbi.nlm.nih.gov/articles/PMC7930850/

  14. Melanotan II User Experience: A Qualitative Study of Online Discussion Forums

    Gilhooley E, Daly S, McKenna D · Dermatology, 2021

    https://pubmed.ncbi.nlm.nih.gov/34464955/

  15. Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report

    Bonchev A · Life (via PMC), 2026

    https://pmc.ncbi.nlm.nih.gov/articles/PMC12942211/

  16. Insights into Tanning Biology and Tanning Products

    Resnick G, Khajeh-Afzaly M, Yousefian F, Raza A, Issa NT · The Journal of Clinical and Aesthetic Dermatology, 2026

    https://pubmed.ncbi.nlm.nih.gov/41890775/

  17. Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use

    Vadner DJ, Smith S · JAAD Case Reports (via PMC), 2026

    https://pmc.ncbi.nlm.nih.gov/articles/PMC13279914/

IV. Regulatory Warnings & Compounding

7 sources
  1. Warning against the tanning product Melanotan

    Danish Medicines Agency · Danish Medicines Agency (Lægemiddelstyrelsen, 20 June 2011), 2011

    https://laegemiddelstyrelsen.dk/en/pharmacies/medicines-imported-from-abroad/warnings-against-products/warning-against-the-tanning-product-melanotan/

  2. FOI 24/274 – Side effects reports of melanotan II products

    Medicines and Healthcare products Regulatory Agency (MHRA) · UK Medicines and Healthcare products Regulatory Agency (17 April 2024), 2024

    https://assets.publishing.service.gov.uk/media/669fbd3aa3c2a28abb50d55a/Final_Redaction_FOI_24_274.pdf

  3. Don’t risk using tanning products containing melanotan

    Therapeutic Goods Administration (TGA) · Australian Government, Therapeutic Goods Administration (24 January 2025), 2025

    https://www.tga.gov.au/news/blog/dont-risk-using-tanning-products-containing-melanotan

  4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks

    U.S. Food and Drug Administration (FDA) · U.S. Food and Drug Administration (Content current as of 04/22/2026), 2026

    https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

  5. Consumer advisory: Unapproved peptide products health warning

    Medsafe (New Zealand Medicines and Medical Devices Safety Authority) · Medsafe New Zealand (21 May 2026), 2026

    https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp

  6. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (91 FR 68526)

    Office of the Secretary, U.S. Department of Health and Human Services (HHS) · Federal Register (October 30, 2026), 2026

    https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances

  7. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Draft Policy Text and Appendices A & B)

    U.S. Department of Health and Human Services (HHS) · U.S. Department of Health and Human Services (announced October 30, 2026 via 91 FR 68526), 2026

    https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf